Halozyme Therapeutics Inc [HALO] stock prices are up 2.79% to $68.05 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HALO shares have gain 4.05% over the last week, with a monthly amount glided 1.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on October 14, 2025, when Leerink Partners upgraded its rating to a Market Perform but kept the price target unchanged to $70 for it. Previously, Morgan Stanley upgraded its rating to Overweight on August 06, 2025, and kept the price target unchanged to $75. Morgan Stanley downgraded its rating to a Equal-Weight but stick to its price target of $62 on May 14, 2025. Leerink Partners downgraded its rating to a Underperform but $47 remained the price target by the analyst firm on May 13, 2025. Wells Fargo downgraded its rating to Equal Weight for this stock on October 07, 2024, and upped its price target to $62. In a note dated September 19, 2024, JP Morgan downgraded a Neutral rating on this stock and boosted its target price from $52 to $57.
The stock price of Halozyme Therapeutics Inc [HALO] has been fluctuating between $42.01 and $79.50 over the past year. Currently, Wall Street analysts expect the stock to reach $82.75 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $68.05 at the most recent close of the market. An investor can expect a potential return of 21.6% based on the average HALO price forecast.
Analyzing the HALO fundamentals
The Halozyme Therapeutics Inc [NASDAQ:HALO] reported sales of 1.24B for trailing twelve months, representing a surge of 22.12%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.58%, Pretax Profit Margin comes in at 0.59%, and Net Profit Margin reading is 0.47%. To continue investigating profitability, this company’s Return on Assets is posted at 0.27, Equity is 1.37 and Total Capital is 0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 4.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 65.39 points at the first support level, and at 62.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 70.32, and for the 2nd resistance point, it is at 72.59.
Ratios To Look Out For
It’s worth pointing out that Halozyme Therapeutics Inc [NASDAQ:HALO]’s Current Ratio is 1.59. As well, the Quick Ratio is 1.37, while the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 6.40, the price to book ratio is 15.87 and price to earnings (TTM) ratio is 14.30.
Transactions by insiders
Recent insider trading involved Torley Helen, PRESIDENT AND CEO, that happened on Oct 01 ’25 when 20000.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Oct 02 ’25 to sell 20000.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 20000.0 shares on Oct 03 ’25.
